Concurrent Inhibition of Akt and ERK Using TIC-10 Can Overcome Venetoclax Resistance in Mantle Cell Lymphoma
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Concurrent Inhibition of Akt and ERK Using TIC-10 Can Overcome Venetoclax Resistance in Mantle Cell Lymphoma. / Granau, Agnete Marie; Andersen, Pilar Aarøe; Jakobsen, Theresa; Taouxi, Konstantina; Dalila, Nawar; Mogensen, Johanne Bay; Kristensen, Lasse Sommer; Grønbæk, Kirsten; Dimopoulos, Konstantinos.
In: Cancers, Vol. 15, No. 2, 510, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Concurrent Inhibition of Akt and ERK Using TIC-10 Can Overcome Venetoclax Resistance in Mantle Cell Lymphoma
AU - Granau, Agnete Marie
AU - Andersen, Pilar Aarøe
AU - Jakobsen, Theresa
AU - Taouxi, Konstantina
AU - Dalila, Nawar
AU - Mogensen, Johanne Bay
AU - Kristensen, Lasse Sommer
AU - Grønbæk, Kirsten
AU - Dimopoulos, Konstantinos
N1 - Publisher Copyright: © 2023 by the authors.
PY - 2023
Y1 - 2023
N2 - Venetoclax, a BCL-2 inhibitor, has proven to be effective in several hematological malignancies, including mantle cell lymphoma (MCL). However, development of venetoclax resistance is inevitable and understanding its underlying molecular mechanisms can optimize treatment response. We performed a thorough genetic, epigenetic and transcriptomic analysis of venetoclax-sensitive and resistant MCL cell lines, also evaluating the role of the stromal microenvironment using human and murine co-cultures. In our model, venetoclax resistance was associated with abrogated TP53 activity through an acquired mutation and transcriptional downregulation leading to a diminished apoptotic response. Venetoclax-resistant cells also exhibited an upregulation of the PI3K/Akt pathway, and pharmacological inhibition of Akt and ERK with TIC-10 led to cell death in all venetoclax-resistant cell lines. Overall, we highlight the importance of targeted therapies, such as TIC-10, against venetoclax resistance-related pathways, which might represent future therapeutic prospects.
AB - Venetoclax, a BCL-2 inhibitor, has proven to be effective in several hematological malignancies, including mantle cell lymphoma (MCL). However, development of venetoclax resistance is inevitable and understanding its underlying molecular mechanisms can optimize treatment response. We performed a thorough genetic, epigenetic and transcriptomic analysis of venetoclax-sensitive and resistant MCL cell lines, also evaluating the role of the stromal microenvironment using human and murine co-cultures. In our model, venetoclax resistance was associated with abrogated TP53 activity through an acquired mutation and transcriptional downregulation leading to a diminished apoptotic response. Venetoclax-resistant cells also exhibited an upregulation of the PI3K/Akt pathway, and pharmacological inhibition of Akt and ERK with TIC-10 led to cell death in all venetoclax-resistant cell lines. Overall, we highlight the importance of targeted therapies, such as TIC-10, against venetoclax resistance-related pathways, which might represent future therapeutic prospects.
KW - mantle cell lymphoma
KW - PI3K/Akt
KW - TIC-10
KW - venetoclax
U2 - 10.3390/cancers15020510
DO - 10.3390/cancers15020510
M3 - Journal article
C2 - 36672458
AN - SCOPUS:85146755999
VL - 15
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 2
M1 - 510
ER -
ID: 335678231